Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 62.61% is in line with its 5-year average of 61.90%, around the middle of its 5-year range (52.54%–76.81%).
0.71% above its 12-month average of 62.17%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 63.58%.
GROSS MARGIN
62.61%
GROSS MARGIN AVG TTM
62.17%
GROSS MARGIN AVG 3Y
60.89%
GROSS MARGIN AVG 5Y
61.90%
GROSS MARGIN AVG 10Y
62.82%
GROSS MARGIN AVG 15Y
61.86%
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+0.71%
CURRENT VS 3Y AVG
+2.82%
CURRENT VS 5Y AVG
+1.15%
CURRENT VS 10Y AVG
-0.33%
CURRENT VS 15Y AVG
+1.21%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
46.69%
median of 507 covered companies
CURRENT VS SECTOR MEDIAN
+34.10%
vs the sector median at left
ClearPoint Neuro, Inc.
Market Cap
$347.88M
Gross Margin
62.61%
TTM Avg
62.17%
3Y Avg
60.89%
5Y Avg
61.90%
Market Cap
$348.59M
Gross Margin
0.00%
TTM Avg
50.00%
3Y Avg
75.00%
5Y Avg
66.67%
Market Cap
$368.66M
Gross Margin
99.87%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
83.33%
Market Cap
$333.91M
Gross Margin
77.81%
TTM Avg
88.91%
3Y Avg
85.13%
5Y Avg
50.71%
Market Cap
$368.13M
Gross Margin
98.15%
TTM Avg
96.49%
3Y Avg
98.25%
5Y Avg
98.83%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ClearPoint Neuro, Inc. (CLPT) | $347.88M | 62.61% | 62.17% | 60.89% | 61.90% |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $348.59M | 0.00% | 50.00% | 75.00% | 66.67% |
| Embecta Corp. (EMBC)vs › | $348.55M | 59.89% | 63.90% | 65.83% | 67.05% |
| Cabaletta Bio, Inc. (CABA)vs › | $342.42M | 0.00% | 0.00% | 0.00% | 0.00% |
| Agenus Inc. (AGEN)vs › | $353.54M | 29.63% | -10.58% | -43.61% | -33.41% |
| Opus Genetics, Inc. (IRD)vs › | $368.66M | 99.87% | 100.00% | 100.00% | 83.33% |
| C4 Therapeutics, Inc. (CCCC)vs › | $333.91M | 77.81% | 88.91% | 85.13% | 50.71% |
| CapsoVision, Inc. (CV)vs › | $329.76M | 50.88% | 53.58% | 54.49% | 54.49% |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $368.13M | 98.15% | 96.49% | 98.25% | 98.83% |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $369.60M | 93.73% | 92.44% | 93.34% | 78.89% |
Gross Margin
62.6%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 63.58% |
| 2026-03-31 | 62.24% |
| 2025-12-31 | 61.52% |
| 2025-09-30 | 63.20% |
| 2025-06-30 | 60.29% |
| 2025-03-31 | 60.48% |
| 2024-12-31 | 61.28% |
| 2024-09-30 | 59.68% |
| 2024-06-30 | 63.48% |
| 2024-03-31 | 59.24% |
| 2023-12-31 | 58.93% |
| 2023-09-30 | 56.80% |
| 2023-06-30 | 52.54% |
| 2023-03-31 | 58.94% |
| 2022-12-31 | 64.09% |
| 2022-09-30 | 71.49% |
| 2022-06-30 | 62.60% |
| 2022-03-31 | 64.22% |
| 2021-12-31 | 76.81% |
| 2021-09-30 | 66.48% |
| 2021-06-30 | 67.10% |
| 2021-03-31 | 64.86% |
| 2020-12-31 | 61.47% |
| 2020-09-30 | 74.34% |
| 2020-06-30 | 67.64% |
| 2020-03-31 | 70.09% |
| 2019-12-31 | 70.94% |
| 2019-09-30 | 66.42% |
| 2019-06-30 | 60.47% |
| 2019-03-31 | 64.15% |
| 2018-12-31 | 69.73% |
| 2018-09-30 | 69.39% |
| 2018-06-30 | 63.42% |
| 2018-03-31 | 63.72% |
| 2017-12-31 | 60.76% |
| 2017-09-30 | 59.88% |
| 2017-06-30 | 59.59% |
| 2017-03-31 | 62.51% |
| 2016-12-31 | 58.60% |
| 2016-09-30 | 53.70% |
| 2016-06-30 | 52.80% |
| 2016-03-31 | 50.04% |
| 2015-12-31 | 57.21% |
| 2015-09-30 | 55.04% |
| 2015-06-30 | 52.19% |
| 2015-03-31 | 61.84% |
| 2014-12-31 | 28.77% |
| 2014-09-30 | 50.12% |
| 2014-06-30 | 51.47% |
| 2014-03-31 | 57.37% |
| 2013-12-31 | 54.65% |
| 2013-09-30 | 60.59% |
| 2013-06-30 | 47.42% |
| 2013-03-31 | 82.10% |
| 2012-12-31 | 91.20% |
| 2012-09-30 | 88.22% |
| 2012-06-30 | 85.54% |
| 2012-03-31 | 89.63% |
| 2011-12-31 | 79.81% |
| 2011-09-30 | 73.33% |
| 2011-06-30 | 95.80% |
